Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chase Board

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of the American Pharmacists Association : Japha|January 1, 2017
You don't need a title to leadChase Board
Journal of Pharmacy Practice|October 6, 2017
Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With GoutEmily Huneycutt, Chase Board, Jennifer N Clements
Journal of Cardiovascular Pharmacology|May 8, 2020
PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized TherapyChase Board, Michael S Kelly, Michael D Shapiro, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of the American Pharmacists Association : Japha|January 1, 2017
You don't need a title to leadChase Board
Journal of Pharmacy Practice|October 6, 2017
Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With GoutEmily Huneycutt, Chase Board, Jennifer N Clements
Journal of Cardiovascular Pharmacology|May 8, 2020
PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized TherapyChase Board, Michael S Kelly, Michael D Shapiro, et al.
Pageof 1